TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits Expectations

Key Points

• EPS met expectations at ($0.22) but revenue materially missed—$0.98M vs. $2.50M est—and the company remains deeply unprofitable (net margin -1,256.81%, ROE -79.36%).
• Shares rose modestly 0.4% to $1.22 with a market cap of about $69.1M, high liquidity ratios (quick/current ratio 8.41) and heavy institutional ownership (≈82.8%).
• Analyst views are mixed: the consensus rating is Hold with a $6.00 target, though Wedbush recently raised its price target to $5 and rated it "outperform" while other firms have issued downgrades.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, meeting the consensus estimate of ($0.22), FiscalAI reports. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. The business had revenue of $0.98 million during the quarter, compared to analyst estimates of $2.50 million.

TScan Therapeutics Stock Up 0.4%

Shares of TScan Therapeutics stock traded up $0.01 on Wednesday, reaching $1.22. The stock had a trading volume of 660,024 shares, compared to its average volume of 733,763. The company has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.17. The company has a quick ratio of 8.41, a current ratio of 8.41 and a debt-to-equity ratio of 0.26. TScan Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.57. The stock has a market capitalization of $69.13 million, a P/E ratio of -1.22 and a beta of 1.06.

Institutional Trading of TScan Therapeutics

Large investors have recently made changes to their positions in the business. Boothbay Fund Management LLC boosted its holdings in shares of TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company's stock valued at $35,000 after acquiring an additional 8,121 shares during the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of TScan Therapeutics in the 4th quarter valued at $25,000. HRT Financial LP purchased a new stake in shares of TScan Therapeutics in the 4th quarter valued at $26,000. Voleon Capital Management LP purchased a new stake in shares of TScan Therapeutics in the 3rd quarter valued at $87,000. Finally, Marshall Wace LLP purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at $78,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wedbush boosted their price target on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Thursday, March 5th. Wall Street Zen downgraded shares of TScan Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, TScan Therapeutics has a consensus rating of "Hold" and a consensus target price of $6.00.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.